JP2019513118A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513118A5 JP2019513118A5 JP2018538647A JP2018538647A JP2019513118A5 JP 2019513118 A5 JP2019513118 A5 JP 2019513118A5 JP 2018538647 A JP2018538647 A JP 2018538647A JP 2018538647 A JP2018538647 A JP 2018538647A JP 2019513118 A5 JP2019513118 A5 JP 2019513118A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- humanized antibody
- antibody
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662286269P | 2016-01-22 | 2016-01-22 | |
| US62/286,269 | 2016-01-22 | ||
| US201662290745P | 2016-02-03 | 2016-02-03 | |
| US62/290,745 | 2016-02-03 | ||
| PCT/IB2017/000031 WO2017125815A2 (en) | 2016-01-22 | 2017-01-20 | Immunological reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513118A JP2019513118A (ja) | 2019-05-23 |
| JP2019513118A5 true JP2019513118A5 (enExample) | 2020-11-19 |
| JP7089474B2 JP7089474B2 (ja) | 2022-06-22 |
Family
ID=58159109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538647A Active JP7089474B2 (ja) | 2016-01-22 | 2017-01-20 | 免疫学的試薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10294299B2 (enExample) |
| EP (2) | EP3964529B1 (enExample) |
| JP (1) | JP7089474B2 (enExample) |
| CN (1) | CN109311981B (enExample) |
| AU (1) | AU2017208819B2 (enExample) |
| CA (1) | CA3012075A1 (enExample) |
| DK (1) | DK3964529T3 (enExample) |
| ES (1) | ES3034233T3 (enExample) |
| FI (1) | FI3964529T3 (enExample) |
| PL (1) | PL3964529T3 (enExample) |
| PT (1) | PT3964529T (enExample) |
| WO (1) | WO2017125815A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3177644T3 (pl) * | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunologiczne reagenty wiążące do PD-1 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| WO2017125815A2 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| CN110392694B (zh) | 2016-11-02 | 2023-08-04 | 震动疗法股份有限公司 | 针对pd-1的抗体及其用途 |
| CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| US12384830B2 (en) | 2017-06-02 | 2025-08-12 | Regents Of The University Of Minnesota | Compositions and methods for improving immunotherapy |
| US20210363255A1 (en) * | 2018-04-04 | 2021-11-25 | Truebinding, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| WO2020010189A1 (en) * | 2018-07-06 | 2020-01-09 | Children's Medical Center Corporation | Methods and compositions for analyzing platelets by mass cytometry |
| WO2020069439A1 (en) * | 2018-09-27 | 2020-04-02 | Musc Foundation For Research Development | Pharmaceutical combination for the treatment of cancer |
| EP3636284A1 (en) * | 2018-10-11 | 2020-04-15 | NBE Therapeutics AG | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| BR112021013008A2 (pt) * | 2019-01-11 | 2021-11-23 | Wistar Inst | Composição para gerar um ou mais anticorpos antiproteína de morte celular programada 1 (pd-1) ou fragmentos dos mesmos, método para tratar uma doença, e, método para aumentar uma resposta imune |
| US20220372148A1 (en) | 2019-07-05 | 2022-11-24 | Ono Pharmaceutical Co., Ltd. | A pharmaceutical composition for treating hematological cancer |
| WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| CN111690070A (zh) * | 2020-05-13 | 2020-09-22 | 深圳市众循精准医学研究院 | 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用 |
| ES3047733T3 (en) * | 2020-06-11 | 2025-12-04 | Univ Iwate Medical | Humanized anti-gpc-1 antibody |
| EP4373851A2 (en) | 2021-07-19 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| JP2024534787A (ja) | 2021-08-16 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規なｉｌ２７受容体アゴニスト及びその使用方法 |
| US20250340668A1 (en) | 2022-05-11 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
| JP2025519158A (ja) | 2022-05-27 | 2025-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターロイキン－２プロタンパク質及びその使用 |
| US20230391844A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| CN117229385A (zh) * | 2022-06-06 | 2023-12-15 | 北京卡替医疗技术有限公司 | Pd-1变体及其用途 |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| JP2025529805A (ja) | 2022-08-18 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターフェロンプロタンパク質及びその使用 |
| EP4638498A1 (en) * | 2022-12-22 | 2025-10-29 | Anaveon AG | Anti-pd-1 antibody antigen-binding domain and immunoconjugate |
| EP4649088A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| US20240287186A1 (en) | 2023-02-28 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| TW202448929A (zh) * | 2023-04-26 | 2024-12-16 | 美商震撼治療有限公司 | 用於調節免疫系統的分子及其用途 |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| US20250179137A1 (en) | 2023-12-05 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025255480A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3011939B2 (ja) | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| WO1991013157A1 (en) | 1990-02-26 | 1991-09-05 | Commonwealth Scientific And Industrial Research Organisation | Shuttle plasmid for escherichia coli and mycobacteria |
| GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU2185592A (en) | 1991-06-06 | 1993-01-08 | Med Immune, Inc. | Induction of ctl responses to foreign antigens expressed in mycobacteria |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JP3454275B2 (ja) | 1992-06-05 | 2003-10-06 | 佑 本庶 | プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ |
| AU7203194A (en) | 1993-06-04 | 1995-01-03 | New York University | Bispecific human monoclonal antibodies specific for human immunodeficiency virus |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| JP2007524348A (ja) | 2003-01-07 | 2007-08-30 | ダイアックス、コープ | クニッツドメインライブラリー |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| EP2439273B1 (en) * | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| KR101888321B1 (ko) * | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| TW201007669A (en) | 2008-08-01 | 2010-02-16 | Integrated Solutions Technology Inc | A display driving device and the driving method thereof |
| WO2010029434A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| CA2790134A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| AU2012236479B2 (en) | 2011-03-31 | 2016-10-20 | Merck Sharp & Dohme Llc | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| US9090994B2 (en) | 2011-06-08 | 2015-07-28 | Nanjingjinsirui Science & Technology Biology Corp. | Antibody humanization by framework assembly |
| MY193562A (en) | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US20150290316A1 (en) | 2012-10-02 | 2015-10-15 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| PL3177644T3 (pl) | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunologiczne reagenty wiążące do PD-1 |
| WO2016106160A1 (en) * | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holdings, Inc. | Methods for screening therapeutic compounds |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| WO2017125815A2 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
-
2017
- 2017-01-20 WO PCT/IB2017/000031 patent/WO2017125815A2/en not_active Ceased
- 2017-01-20 CN CN201780017299.3A patent/CN109311981B/zh active Active
- 2017-01-20 US US15/513,395 patent/US10294299B2/en active Active
- 2017-01-20 EP EP21181607.9A patent/EP3964529B1/en active Active
- 2017-01-20 PL PL21181607.9T patent/PL3964529T3/pl unknown
- 2017-01-20 ES ES21181607T patent/ES3034233T3/es active Active
- 2017-01-20 DK DK21181607.9T patent/DK3964529T3/da active
- 2017-01-20 FI FIEP21181607.9T patent/FI3964529T3/fi active
- 2017-01-20 JP JP2018538647A patent/JP7089474B2/ja active Active
- 2017-01-20 EP EP17707109.9A patent/EP3405497A2/en not_active Withdrawn
- 2017-01-20 CA CA3012075A patent/CA3012075A1/en active Pending
- 2017-01-20 AU AU2017208819A patent/AU2017208819B2/en active Active
- 2017-01-20 PT PT211816079T patent/PT3964529T/pt unknown